Urothelial carcinoma in dogs

Scottish - Carcinome urothélial du chien

 

About Urothelial Carcinoma

Urothelial carcinoma, formerly known as transitional cell carcinoma, is an aggressive tumor accounting for around 2% of canine neoplasia. It is the most common tumor of the urinary tract in dogs, mainly affecting the trigone of the bladder. This cancer can also invade adjacent organs such as the vagina, prostate and pelvic canal.

Grades of tumour

Urothelial carcinoma in dogs is classified according to a grading system based on the World Health Organization (WHO) classification. The TNM system is used to determine :

 

 

T - Primary Tumor

 

 

 

Tis

Carcinoma in situ

 

 

 

 

T0

No evidence of primary tumor

   

 

T1

Superficial papillary tumour

   

 

T2

Tumour with thickening and invasion of the bladder wall

 

T3

Tumour invading neighbouring organs (prostate, uterus, vagina, pelvic canal)

 

N - Regional lymph nodes (internal and external iliac)

 

N0

No involvement of regional lymph nodes

 

 

N1

Regional lymph nodes involved

   

 

N2

Regional and distant lymph nodes involved

 

 

 

 

M - Distant metastasis

 

 

 

M0

No metastasis

 

 

 

 

M1

Distant metastasis

 

 

 

 

 

Diagnosis

Early diagnosis of urothelial carcinoma can be difficult due to the similarity of symptoms to other urinary tract conditions, such as infections. Clinical signs include stranguria (difficulty in urinating), hematuria (blood in the urine) and pollakiuria (frequent urination).

For an accurate diagnosis, several steps are followed: complete clinical examination, urinalysis, medical imaging, biopsy and histological analysis.

Treatment options

Treatment of urothelial carcinoma in dogs may include: surgery (often complex and sometimes impossible due to tumor location), chemotherapy, radiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs).

Call for Participation in a Clinical Study

We are currently recruiting dogs with urothelial carcinoma to participate in a clinical study aimed at understanding the relationship between inflammatory cytokines and the immune response in affected dogs in order to improve its diagnosis, understanding, prognosis estimation and treatment. Dogs must have confirmed or strongly suspected urothelial carcinoma and not have received any previous specific treatment.

Protocol description

The following examinations are carried out during the diagnostic visit:

  • Clinical examination
  • Complete blood count
  • Urinalysis
  • Chest X-ray
  • Abdominal ultrasound
  • Biopsies of bladder or urethral lesion
  • CT scan

In the event of a confirmed diagnosis of urothelial carcinoma, the data will be used for scientific and educational purposes.

Implications for the owner

Give permission for the use of clinical and biological data anonymously to the Clinique Vétérinaire Universitaire in the informed consent form.

Compensation

For any dog presenting for consultation with a bladder mass, with no other comorbidity, and with no current treatment:

  • Consultation
  • Blood test
  • Urinalysis
  • Imaging work-up

How to participate

If you are interested in this study or have any questions about it, please contact Dr Rafael Bernardes at rbernardes@uliege.be or Pr A. Hamaide at Annick.Hamaide@uliege.be

updated on 8/5/24

Share this page

cookieImage